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Although primarily defined by their cardinal antigen-presenting function, dendritic cells (DCs) are also equipped with
cytotoxic properties. We have recently reported that DCs activated by IFNc-secreting Th-1 lymphocytes can kill cancer
cells and subsequently present the acquired tumor-derived antigens to T lymphocytes both in vitro and in vivo.
The prospect of exploiting the antigen
presenting function of DCs to generate
adaptive anti-tumor immunity has
prompted extensive research and clinical
trials to evaluate the therapeutic efficacy of
DC-based cancer vaccines. Besides their
primary role as orchestrators of adaptive
and innate immune responses, many
studies conducted in rodents and humans
have highlighted the possibility that DCs
can also function as direct cytotoxic
effectors against tumors.
1-5 This less con-
ventional aspect of DC biology has
however received limited attention and
controversy has arisen as it relates to the
true origin of these cells, the mode of
induction of and the mechanism(s) under-
lying their killing activity.
2,3,6,7 Whether
and how the cytotoxic function of DCs
may influence their antigen-presenting
function and ability to activate effector
lymphocytes is still debatable.
2-5,8,9
The killing activity of different DC
subpopulations (native DC differentiating
in vivo or DC generated in vitro from
dedicated precursors) may be innate or
triggered by distinct signals including Toll-
like receptor (TLR) agonists such as LPS
or CpG, different cytokines, or CD40L.
In our recent work,
10 we investigated
the possible modulation of mouse bone
marrow-derived DC cytotoxic function by
T lymphocytes. Using B16 melanoma or




+ T helper-1 (Th-1) lympho-
cytes promoted the killing potential of
purified CD11c
+ DC generated from
C57BL/6 or BALB/c mouse bone marrow.
Further investigation of the mechanisms
underlying Th-1-mediated induction of
DC cytotoxic activity indicated that IFNc
played a prominent role in this process.
Indeed, anti-IFNc blocking antibodies
prevented the induction of DC cytotoxic
function and Th-1 lymphocytes failed
at triggering the tumoricidal function of
DCs generated from IFNc receptor
knockout mice.
A variety of cytotoxic mechanisms
responsible for DC-mediated tumor cell
killing have been described which include
the perforin/granzyme system, death
receptor ligands (Fas-L, TRAIL and other
TNF-family members), ROS and/or NO.
We did not detect significant expression of
TRAIL, Fas-L, perforin and granzyme by
Th-1-activated killer DCs (Th-1 KDCs).
Moreover, the tumoricidal function of




2/2 mice was not
impaired compared with that of DC
generated from wild-type mice, excluding
a possible role for these molecules.
Importantly, iNOS expression was signifi-
cantly upregulated in Th-1 KDCs, which
correlated with increased nitrite concen-
tration in the culture supernatants. Con-
firming these observations, the inhibitor
of iNOS, NMMA, abrogated Th-1 KDC-
mediated tumor cell killing and the
cytotoxic activity of DC generated from
iNOS
2/2 mice was significantly impaired,
highlighting the central role of NO in the
tumoricidal function of these cells.
The fact that a same population of cells
can unify cytotoxic and antigen presenting
functions has been subjected to intensive
debate and reservations were raised on the
true antigen presenting capability of
KDCs. A critical question was therefore
to determine whether Th-1 KDCs were
capable of presenting antigens from the
tumor cells they had killed. To address this
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point, Th-1 KDCs were first co-cultured
with B16 melanoma cells expressing the
model antigen ovalbumin (B16-OVA),
re-isolated and either stained with anti-
CD11c and an antibody recognizing
MHC class I-SIINFEKL complexes
(H-2Kb/OVA257–264) or cultured for
24 h with B3Z (a CD8
+ T cell line expres-
sing a TCR which specifically recognizes
the SIINFEKL peptide of OVA in the
context of MHC Class I). H-2Kb-
SIINFEKL complexes were detected at
the surface of isolated CD11c
+ DCs
and purified Th-1 KDCs were capable
of activating B3Z cells. Similar results
were obtained using lymphocytes from
OT-I transgenic mice that specifically
recognize H-2Kb-OVA257–264 complexes
or from OT-II mice (recognizing I-A(d)-
OVA323–339) (see ref. 10 and unpublished
results). These results therefore indicate
that in vitro Th-1 KDCs were able to kill
OVA-expressing B16 and acquire, process
and present ova peptides. In a next step
we explored the significance of these
observations in vivo. CD11c-GFP-DTR
mice bearing established B16-OVA
tumors were treated with DT to deplete
endogenous CD11c
+ DCs and Th-1
KDCs or control non-killer DCs were
injected into the tumor beds. After 36 h
the ability of CD11c
+ DCs isolated from
the tumor draining lymph nodes to
activate specific T lymphocytes was exam-
ined. Interestingly, Th-1 KDCs were
significantly more efficient than non-
killer DCs at inducing B3Z activation
and OT-I and OT-II T lymphocyte
proliferation. These results therefore
demonstrate that Th-1-activated killer
DCs were capable of migrating from the
tumor site to the lymph nodes, and that
functionally these killer DCs had the
ability to process and present in a MHC
Class I and Class II-restricted manner
the tumor-derived antigens acquired in
vivo (Fig.1). This capacity of Th-1 KDCs
to efficiently present antigens was con-
tingent upon induction of their killing
function.
Harnessing the potential of KDC to act
as killers and messengers may provide
multiple advantages which may revitalize
their attractiveness as anti-cancer vaccines.
By participating in the direct elimination
of tumor cells, KDC may contribute to
diversify the immune cytotoxic effector
mechanisms. More importantly, from an
immunological perspective, by allowing
for the rapid uptake of released tumor
antigens, before their clearance by
scavenger neutrophils or macrophages,
KDC-mediated tumor cell killing is of
considerable relevance for the acquisition
of tumor-derived material in a more
efficient manner. In line with this idea,
Figure1. Antigen presenting function of Th-1 KDCs administered in vivo. Th-1-activated KDCs
injected intratumorally to DT-treated B16-OVA-bearing CD11c-GFP-DTR mice migrated to the tumor
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further studies are required to determine
whether KDC may promote a more
immunogenic type of cancer cell death
which may foster tumor antigen uptake,
processing and presentation. It will also
be essential to clearly delineate the
potential advantages of using KDC
(either KDC purified after killing of
tumor cells in vitro, or KDC directly
injected into the tumor beds) over con-
ventional tumor-antigen loaded DC as
cancer vaccines.
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